Contact hours available until 11/3/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:

Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation

Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab

There are no other disclosures to declare.

Commercial Support and Sponsorship:
Sponsored by Astellas Pharma US, Inc.

Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.

Objectives:
• Critically assess evidence based treatment options for castration-resistant prostate cancer focusing on new and emerging therapies.
• Recognize and manage disease and treatment related complications with the goal of developing a plan of care to improve quality of life and continuation of care.
• Summarize the available efficacy and safety data related to new and novel agents used for the treatment of prostate cancer that has progressed during androgen-blockade.
• Evaluate patient and disease characteristics and identify opportunities to provide.
• comprehensive care and counsel of patients with metastatic CRPC.

Thomas Keane MD

Appearances